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ABSTRACT
The endemic state of methicillin-resistant Staphylococcus aureus (MRSA) occurs through a constant inﬂux
of MRSA into the healthcare setting from newly admitted MRSA-positive patients, followed by cross-
transmission among inpatients and an efﬂux of MRSA from the hospital with discharged patients. To
date, most MRSA prevention strategies have targeted cross-transmission among hospitalised patients.
Intensive concerted interventions that include isolation can reduce the MRSA incidence substantially.
However, debate continues about the cost-effectiveness of infection control policies, including screening
protocols, to control the inﬂux of MRSA into hospitals. The rationale and cost-effectiveness of wide
screening, as compared to targeted screening, should be further studied using appropriate statistical
approaches and economic modelling.
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Methicillin-resistant Staphylococcus aureus (MRSA)
has been a common nosocomial pathogen since
the 1960s and is now a major problem in hospitals
worldwide [1]. A recent study of 216 644 inpa-
tients in the UK revealed that rates of S. aureus
bacteraemia rose signiﬁcantly between 1997 and
2003, and that MRSA was responsible for this
increase [2]. In 2005, the European Antimicrobial
Resistance Surveillance System (EARSS) reported
percentages of methicillin resistance ranging from
0% in Iceland to 61.4% among S. aureus isolates
in Romania (http://www.earss.rivm.nl). In the
same year, data from The Surveillance Network-
USA (TSN), which collects data from 300 clinical
microbiology laboratories across the USA,
reported MRSA rates of 59%, 55% and 48% for
isolates from non-intensive care unit (ICU) inpa-
tients, ICU patients and outpatients, respectively
[3]. However, a recent systematic review of
policies for the hospital management of MRSA
demonstrated that intensive concerted interven-
tions that include isolation policies can substan-
tially reduce MRSA rates, even in settings with a
high level of endemic MRSA [4].
To develop effective prevention strategies, it is
ﬁrst necessary to understand the various compo-
nents responsible for an endemic state. In recent
years, MRSA has been diagnosed with increasing
frequency upon hospital admission [5]. In a cohort
study of 127 patients with MRSA bacteraemia
diagnosed upon admission, independent risk-fac-
tors included a history of MRSA colonisation or
infection within the preceding 90 days, the pres-
ence of a central venous catheter (CVC), and skin
ulcers or cellulitis [5]. These ‘community-acquired’
MRSA strains arise from two different patient
populations: those with true community-acquired
MRSA strains that have emerged de novo from
community-based S. aureus strains, and health-
care-associated strains that have been acquired
during a previous exposure to a healthcare setting
or intervention. The latter patient population is
twice as likely to harbour MRSA than individuals
without exposure to a healthcare setting [6]. Once
admitted to the hospital, this patient population
can serve as an important reservoir of MRSA,
contributing substantially to patient-to-patient
transmission and to MRSA dissemination. The
CDC has recently updated guidelines for prevent-
ing transmission of infectious agents in healthcare
settings (http://www.cdc.gov/ncidod/dhgp/pdf/
isolation2007.pdf). Among other changes, the term
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‘nosocomial infections’ is replaced by ‘healthcare-
associated infections’ to reﬂect changing pat-
terns in healthcare delivery and the difﬁculty
in determining the geographical site of exposure
to an infectious agent and ⁄ or acquisition of
infection. For physicians, this new categorisation
of infections has a signiﬁcant impact on the
choice of empirical therapy for infections diag-
nosed upon admission and on infection control
policies.
Whether MRSA screening upon admission is
worthwhile remains a matter of debate. UK and
US guidelines recommend that patients should
be screened routinely before admission to an
ICU in a hospital where MRSA is endemic [7,8].
In an endemic setting in France, where the
prevalence of MRSA carriage upon ICU admis-
sion was 7%, risk-factors associated with MRSA
carriage were an age >60 years, transfer from
other departments or hospitals, prolonged hos-
pitalisation in other wards, previous hospitalisa-
tion for surgery, and the presence of open skin
lesions. Using a cost–beneﬁt analysis, it was
demonstrated that universal screening and iso-
lation were beneﬁcial in this setting [9]. Another
study evaluated the impact of different compo-
nents of a screening programme for MRSA
carriers upon hospital admission on the value
of two risk-adjusted rates: the proportion of
imported MRSA as an indicator of the MRSA
colonisation pressure, and the incidence of nos-
ocomial MRSA [10]. Screening patients with risk-
factors resulted in a 51% increase in the calcu-
lated proportion of imported strains and a 58%
decrease in the indicator of the MRSA colonisa-
tion pressure.
In 2006, legislation that made mandatory the
use of active surveillance cultures to screen
hospitalised patients for colonisation by MRSA
and vancomycin-resistant enterococci were intro-
duced in two US states. In response, the Society
for Healthcare Epidemiology of America (SHEA)
and the Association for Professionals in Infection
Control and Epidemiology Inc. (APIC) developed
a position statement asserting that, although
evidence supporting the use of active surveillance
for high-risk patients and during outbreaks is
available, there is insufﬁcient evidence to justify
the mandatory use of this control measure. The
lack of support for this legislation is related to the
uncertainties and the potential unintended con-
sequences, which include the exclusion of local
infection control professionals from their role in
leading risk assessments and resource allocation,
the still open controversies regarding the epide-
miological, biological and clinical implications of
active surveillance, and the potential negative
effects on patients of contact isolation [11]. Tar-
geted surveillance of the highest-risk patients in
medical or surgical wards might be a more
effective use of resources. In a surveillance study,
independent risk measures for MRSA upon
admission were a previous stay in a nursing
home, previous MRSA infection, and a third
variable, representing the combined effects of
homelessness, imprisonment, promiscuity, and
intravenous and other drug use. Multivariable
models had greater sensitivity for detecting
MRSA upon admission than any single risk
measure, and allowed detection of 78–90%
of MRSA strains from admission surveillance
cultures for 46–58% of admissions [12].
Risk-factors for nosocomial MRSA have been
extensively studied and include underlying
disease, previous hospitalisation, use of antimi-
crobial agents, surgery, length of hospitalisation,
a CVC and endotracheal intubation, enteral
feeding, admission to the ICU, high nursing
staff workload, and non-compliance with hand
disinfection procedures [13,14]. A 12-month
Italian multicentre study of 864 inpatients start-
ing antibiotic treatment revealed that the inci-
dence of newly acquired nasal colonisation by
MRSA per 1000 days of therapy was 8.2 for
macrolides, 7.9 for carbapenems, 3.2 for glyco-
peptides, 3.1 for quinolones, and 2.4 for third-
generation cephalosporins. The highest rates
were revealed for carbapenem use in diabetic
and dialysed patients (47th Interscience Confer-
ence on Antimicrobial Agents and Chemother-
apy, Chicago, 2007; C2-2037). A 1-year study in
an ICU in a university hospital in the UK
[15] revealed that urgent admission, high
APACHE II score at 24 h, bronchoscopy and
days of staff deﬁcit were all independent risk-
factors for nosocomial MRSA acquisition. Staff
shortage was the only factor associated signiﬁ-
cantly with cross-transmission. It was predicted
that a 12% improvement in adherence to hand
hygiene guidelines might have compensated for
staff shortage and prevented transmission dur-
ing periods of overcrowding, shared care and
high workload, but this would be difﬁcult to
achieve.
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Risk assessment forMRSAmight be different for
speciﬁc populations, e.g., patients with human
immunodeﬁciency virus infection. In retrospective
case-control studies before hospitalisation, expo-
sure to broad-spectrum antibiotics, the presence of
a CVC, dermatological disease, a high APACHE II
score and human immunodeﬁciency virus vira-
emia were independent risk-factors for the devel-
opment of MRSA infection or colonisation in this
population [16,17].
Topical mupirocin might be useful for decoloni-
sation of healthcare workers or selected patients
colonised with MRSA. A meta-analysis [18]
revealed that mupirocin therapy reduced the risk
of developing a S. aureus infection by 68% among
dialysis patients. In non-general surgery, the use of
mupirocin was associated with a 20% reduction in
surgical site infection in randomised trials, and
with a 60% reduction in before–after trials [19].
Most recently, rapid methods for molecular detec-
tion of MRSA have been developed [20, 21].
However, evidence currently available does not
suggest their routine use. Further studies are
required to evaluate the cost-effectiveness of these
methods and their application in speciﬁc epide-
miological settings (e.g., ICU vs. general and
surgical wards).
In conclusion, preventing MRSA transmission
is important because infections are associated
with considerable mortality and excess hospital
costs. Despite much debate about the evidence
and the cost-effectiveness of various infection
control policies, the majority of prevention strat-
egies in hospitals have targeted the middle
component of the endemic state, i.e., cross-trans-
mission among hospitalised patients. Knowledge
of the variables that identify patients at higher
risk of being carriers or infected with MRSA may
assist clinicians in targeting preventive measures
and streamlining vancomycin use. Targeted
screening could be used to limit the potential for
MRSA dissemination from unrecognised patient
reservoirs at the start of their hospitalisation, as
opposed to other strategies that target patients
who are already hospitalised. Although the inﬂux
of MRSA into the hospital would not change, the
beneﬁt of early detection would be to reduce the
period during which these patients disseminate
MRSA. Further studies on the efﬁcacy of isolation
policies in different epidemiological settings,
using appropriate statistical approaches and eco-
nomic modelling, are needed.
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